Lumida
/NMRA
⌘K
Neumora Therapeutics Inc

Neumora Therapeutics Inc

NMRA
$1.20USD-4.00%-0.05 today

MARKET CAP

225.5M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$4

AI Summary

Stalk
Buy NowMedium

NMRA is basing in an early Stage 1 consolidation with price forming higher highs and higher lows above the short-term EMAs, signaling stabilization and a foundation for a trend reversal. Short-term EMAs (9/21) have shifted to support and price is holding above them, offering a favorable pullback entry. The active Higher Highs & Higher Lows pattern indicates demand dominance and a bullish medium-term stance, despite the long-term downtrend persisting.

  • Seven clinical programs including NMRA 511 and Nevacopran address major unmet neurotherapeutic needs.
  • COSTAL 1 top-line data due by year-end 2025, a key valuation catalyst.
  • Q1 2025 net loss widened to $68 M; Q3 2024 opex at $76.6 M intensifies cash burn.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICTREND
Sales, Adj.
YoY %
P / Sales
EV / Sales
Gross Profit, Adj.
YoY %
Margin %
EV / Gross Profit
EBITDA, Adj.
YoY %
Margin %
EV / EBITDA
EBIT
YoY %
Margin %
EV / EBIT
Net Income
YoY %
Net Margin
EPS (GAAP)
YoY %